InvestorsHub Logo
Followers 42
Posts 2198
Boards Moderated 0
Alias Born 02/10/2014

Re: NEW4THIS post# 407

Sunday, 04/13/2014 4:12:57 PM

Sunday, April 13, 2014 4:12:57 PM

Post# of 2205
Nice article. According to the abstract of the Pubmed article (http://www.ncbi.nlm.nih.gov/pubmed/24390344), as well as the link you just posted, I noticed 2 things. #1. A humanized mouse liver cell is different than an actual human liver cell. Hopefully that will work to our favor. #2. Even if there happened to be a 20% decrease in the efficiency of the viral vector to be transduced into human liver cells, it only stands to reason then that you would "flood" the liver with such viral vectors until saturation is achieved. And nowhere in the article does it say that ddRNAi doesn't do what it is supposed to. It just alludes at the possibility that it may have a reduced efficiency at transduction.

I'm still confident unless human clinical trials dictate otherwise. I just personally think that Benitec is a pioneer on the cutting edge of gene-therapy. Is it possible the platform could be tweaked to be even better? Maybe. For now, the platform that they do have looks pretty kick-butt to me.

All in my opinion! Great link, NEW! Thanks!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTC News